The fact
Meanwhile, the pharmaceutical group scales back its replacement project in Basel.
This decision reflects growing fiscal and regulatory challenges in Switzerland.
Click the link to read an article on the topic:
Meanwhile, the pharmaceutical group scales back its replacement project in Basel.
This decision reflects growing fiscal and regulatory challenges in Switzerland.